Embryonic stem cell therapy of heart failure in genetic cardiomyopathy

Satsuki Yamada1, Timothy J Nelson, Ruben J Crespo-Diaz

  • 1Department of Medicine, Division of Cardiovascular Diseases, Marriott Heart Disease Research Program, Mayo Clinic, Rochester, Minnesota, USA. 55905, USA. terzic.andre@mayo.edu

Insights

Embryonic stem cell therapy successfully repaired genetic dilated cardiomyopathy in a mouse model, reversing heart failure and improving survival. This offers a potential new treatment for inherited heart conditions.

Area of Science:

  • Cardiovascular Research
  • Regenerative Medicine
  • Genetics

Background:

  • Nonischemic cardiomyopathies, often heritable, lack effective repair therapies.
  • Human dilated cardiomyopathy 10 (CMD10) is linked to mutations in cardiac ATP-sensitive K(+) (K(ATP)) channel subunits.
  • Previous studies showed embryonic stem cell benefits in ischemic heart disease, but not inherited cardiomyopathy.

Purpose of the Study:

  • To test the efficacy of embryonic stem cell therapy in a genetic model of nonischemic cardiomyopathy.
  • To investigate the reparative capacity of stem cells in inherited heart failure.

Main Methods:

  • A Kir6.2-knockout mouse model was used, mimicking CMD10 under pressure overload.
  • Embryonic stem cells were delivered epicardially to the left ventricular wall.
  • Cardiac function, remodeling, engraftment, and survival were assessed post-transplantation.

Main Results:

  • Stem cell therapy reversed systolic dysfunction and electrical abnormalities within one month.
  • Maladaptive remodeling was halted, preventing end-stage organ failure.
  • Stem cells engrafted, formed cardiac tissue, activated cell cycle, reduced fibrosis, and normalized heart structure.

Conclusions:

  • Embryonic stem cells achieve functional repair in nonischemic genetic cardiomyopathy.
  • This therapy expands treatment options for heritable heart failure.
  • Stem cell transplantation offers a promising approach for inherited cardiomyopathies.